StockTwits Midday Q&A Series: Adam Feuerstein
- ppearlman
- May 31st, 2011
On Wednesday June 1, StockTwits will begin a new on stream feature called the StockTwits Midday Q&A.
Our first featured guest is TheStreet senior columnist Adam Feuerstein who will be fielding questions on the StockTwits stream regarding cancer drug development just prior to the 2011 American Society of Clinical Oncology Annual Meeting (ASCO 2011) which begins this Friday.
ASCO 2011 is a huge deal in the biotechnology space and if you trade or invest in names like $EXEL, $YMI, $INCY or $NEOP you will not want to miss.
Adam is the axe among biotech journalists who digs deep for the real story and dares to offer unpopular opinions and tell it like it is. You can find his archives here to catch up on what might be in play going into the meeting.
It is a timely Q&A session too given the ASCO meeting this weekend and the volaitility we will likely see on Friday and into next week among biotech stocks.
To follow the Q&A, simply follow @adamfeuerstein on StockTwits or the ticker $EXCHTALK. To ask a question, simply send an @ reply message to @adamfeuerstein from StockTwits or include the ticker $EXCHTALK in your post starting at 11:30 (30 minutes before the Q&A begins).
If you would like to be featured in a future Midday Q&A session, please email me at Phil at StockTwits dot com.
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.
Tickers: Adam Feuerstein, ASCO 2011, EXEL, INCY, NEOP, StockTwits Midday Q&A, YMI
blog comments powered by Disqus-
StockTwits® is an open, community-powered idea and information service for investments. Users can eavesdrop on traders and investors, or contribute to the conversation and build their reputation as savvy market wizards. The service takes financial related data and structures it by stock, user, reputation, etc. More »
-
Archives
-